Our officers and directors are as follows: Name ​ ​ Age ​ ​ Position ​ Dr. Cornelius Boersch ​ ​ 53 ​ ​ Chief Executive Officer and Director ​ Daniel Wenzel ​ ​ 43 ​ ​ Chief Investment Officer ​ Alexander Hornung ​ ​ 26 ​ ​ Chief Financial Officer ​ Prof. Dr. Utz Claassen ​ ​ 58 ​ ​ Chief Operating Officer and Director (nominee) ​ Miles Gilburne ​ ​ 70 ​ ​ Director (nominee) ​ Winston Ma ​ ​ 47 ​ ​ Director (nominee) ​ Dr. Phillip Rösler ​ ​ 48 ​ ​ Director (nominee) ​ Dr. Cornelius Boersch Dr. Cornelius Boersch will serve as our Chief Executive Officer and is a non-independent member of our Board. Dr. Boersch is the founder of MP and has been an entrepreneur, investor and founder of numerous technology companies for the past 25 years. He will lead Mountain & Co. I Acquisition Corp. as Chief Executive Officer and also serve as a non-independent member of our Board of Directors. Dr. Boersch founded his first company in 1991 and developed it into the smart card broker and RFID-producer ACG AG (1995) and successfully listed it on the Frankfurt Stock Exchange in 1999. The company grew to a market cap of over €1 billion. Subsequently, Dr. Boersch initiated the development of further RFID-based companies, such as Smartrac (IPO in 2006), and NASDAQ-listed Identiv. Since founding MP, Dr. Boersch focused on investments in, and the development of, high growth internet and technology companies. Dr. Boersch was named Entrepreneur of the Year 2000, European Business Angel of the Year 2009 and is currently one of the most active and highly-recognized business angels in Europe. Since 2015, his personal investments have been co-financed by the European Investment Fund on a 1:1 co-investment basis. The European Investment Fund has allocated €800 million to its co-investment program with approximately 120 carefully selected investors, of which Dr. Boersch, with more than 50 investments in 44 technology companies to his name, is currently the largest. In the course of his career, he has led 12 IPOs, over 50 trade sales and has been involved in more than 350 tech investments. Notable investments include Alando, Lieferando, Autoscout, Immoscout, Secusmart, Rebuy, Ciao, Bab.la, Shirtinator, Exasol, Wefox, Lingoda, Flash Coffee, fayteq and Kavak, amongst many others. He studied at the European Business School in Oestrich-Winkel and earned his Ph.D. from the University of Duisburg in Essen. Daniel S. Wenzel Mr. Wenzel will serve as our Chief Investment Officer. Mr. Wenzel is the co-founder of MP and has built the company together with Dr. Boersch since 2005. Before the foundation of MP, Mr. Wenzel was CEO of Dr. Boersch’s private family office. Prior to that, he initiated the corporate office of Smart Card Brokers and RFID manufacturer ACG AG and was in charge of strategy projects, M&A transactions and financings. At the beginning of his career, Mr. Wenzel worked at Dresdner Bank and BNP Paribas in Latin America, and at Bain & Company. He studied Business Administration at WHU Koblenz — Otto Beisheim School of Management, at Helsinki School of Economics and at Universidad Adolfo Ibañez in Chile. Mr. Wenzel is Honorary Consul of the Republic of Chile in Switzerland. Alexander Hornung Alexander Hornung will be our Chief Financial Officer. Mr. Hornung is the co-founder and board member of Conny & Co. AG and has grown the company together with Dr. Boersch since its inception in 2019. His collaboration with Dr. Boersch began during his studies of law and business at the European Business School, when Dr. Boersch backed Mr. Hornung’s first entrepreneurial activities. Mr. Hornung gained experience in international capital markets law with Skadden, Arps, Slate, Meagher & Flom LLP (Frankfurt 115 TABLE OF CONTENTS am Main, Germany) and large-scale cross border investing at Silk Road Finance Corporation (Hong Kong, S.A.R.) and Chinastone Capital Management Ltd. (Beijing, China). He joined MP in 2018. At MP, Mr. Hornung serves as Investment Director for the Asian portfolio and focuses on the internationalization of technology companies between Europe, Asia and the Americas. He holds a Bachelor of Laws and a Master of Arts in Business for Legal Professionals from European Business School as well as a Master in Management and Economics from the Yenching Academy of Peking University. Prof. Dr. Utz Claassen Prof. Dr. Claassen will serve as our Chief Operating Officer and a non-independent member of our board. Prof. Dr. Claassen is a manager, management consultant, entrepreneur, investor, scientist, publicist and author with broad international experience. Prior to joining us, Prof. Dr. Claassen was responsible for and succeeded in three major, large-scale corporate restructuring and turnaround processes, namely Seat, Sartorius and EnBW. At Seat, Prof. Dr. Claassen managed a stringent and successful restructuring after its 1993 loss of approximately 2 billion Deutsche Mark, returning to profit after three years as a result of substantial cost reductions in all areas through the introduction of product business plans and profit-oriented sales controlling. Then he spearheaded the successful restructuring of Sartorius, which increased the company’s market capitalization by approximately 50% (adjusted for stock splits and capital increases) between 1997 and 2003. Today, Sartorius has a market capitalization of approximately €29 billion. Prof. Dr. Claassen also led a swift and successful restructuring of EnBW from losses before taxes exceeding €1 billion to profit before taxes exceeding €1 billion within less than two years, achieved through significant cost reductions, concentration on the core business and stringent professionalization of structures and processes. Prof. Dr. Utz Claassen is the founder (2008), main shareholder and Chairman of the Executive Board and CEO of Syntellix, a medical technology company specializing in highly innovative, bioabsorbable metallic implants. He has served on over 50 boards and advisory boards, and in various senior management positions, including as chairman of the executive boards at EnBW Energie Baden-Württemberg AG, Sartorius AG, Solar Millennium AG and as a member of the executive committee of Electricité de France, S.A. (EDF). Prof. Dr. Claassen studied Economics and Management at the universities of Hannover and Oxford and holds a PhD from the University of Hannover. Miles Gilburne Mr. Gilburne, will serve as an independent non-executive member of our Board of Directors. Mr. Gilburne has been active for more than 25 years as a venture capitalist, corporate strategist and technology lawyer with substantial experience in media, communications, information technology and healthcare. He founded and manages ZG Ventures, a U.S.-based venture capital firm. Prior to forming ZG Ventures in 2000, Mr. Gilburne served for five years as Senior Vice President of Corporate Development for AOL, where he was responsible for strategic planning and for major corporate acquisitions, joint ventures and alliances. In this position, he played a leading role in the world’s second largest M&A transaction to date between AOL and Time Warner at a transaction value of $165 billion. He was elected to the board of directors of AOL in 1999 and continued to serve on the board of directors of Time Warner, Inc. until stepping down in May 2006. Winston Ma, CFA Winston Ma will serve as an independent non-executive member of our Board of Directors. Mr. Ma is a former Managing Director and Head of North America office for China Investment Corporation (“CIC”), where he had senior roles in about $20 billion cross-border investments. Mr. Ma set up West Summit (Huashan) Capital in 2010, CIC’s first overseas tech investment, whose notable investments included twitch and unity. Being an investor, attorney, author, and adjunct professor in the global digital economy, Mr. Ma’s expertise lies in in the global digital economy, cross border investments, and multinational law and policy. Before joining CIC, Mr. Ma held positions as a corporate lawyer at Davis Polk Wardwell LLP and as an investment banker at J.P. Morgan. Dr. Philipp Rösler Dr. Rösler will serve as an independent non-executive member of our Board of Directors. Dr. Rösler is a former German politician, who served as Federal Minister of Health and later of Economics and Technology 116 TABLE OF CONTENTS and as well as Vice Chancellor of Germany from 2009 to 2013. He was also Chairman of the FDP from 2011 to 2013. Dr. Rösler was Managing Director of the World Economic Forum, and holds board seats in several TMT companies, including Siemens Healthineers, Brainloop, Bertelsmann Stiftung and many others. Previous board positions include Volkswagen, ZDF and KfW. Number and Terms of Office of Officers and Directors Our Board of Directors is divided into three classes, with only one class of directors being appointed in each year, and with each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term. In accordance with the Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on the Nasdaq. The term of office of the first class of directors, consisting of Winston Ma and Dr. Philipp Rösler, will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Miles Gilburne, will expire at our second annual general meeting. The term of office of the third class of directors, consisting of Dr. Cornelius Boersch and Prof. Dr. Utz Claassen, will expire at our third annual general meeting. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason. Pursuant to an agreement to be entered into on or prior to the closing of this offering, our sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for appointment to our Board of Directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our Board of Directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association will provide that our officers may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our Board of Directors be independent. Our Board of Directors has determined that Miles Gilburne, Dr. Phillip Rösler and Winston Ma are “independent directors” as defined in the Nasdaq listing standards. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on the Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will reimburse an affiliate of our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our sponsor, executive officers and directors, or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. 117 TABLE OF CONTENTS Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our Board of Directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our Board of Directors will have three standing committees: an audit committee, a nominating committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of the Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of the Nasdaq require that the compensation committee and the nominating committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Miles Gilburne, Dr. Phillip Rösler and Winston Ma will serve as members of our audit committee. Our Board of Directors has determined that each of Miles Gilburne, Dr. Phillip Rösler and Winston Ma are independent under the Nasdaq listing standards and applicable SEC rules. Winston Ma will serve as chairman of the audit committee. Under the Nasdaq listing standards and applicable SEC rules, all the directors on the audit committee must be independent. Each member of the audit committee is financially literate and our Board of Directors has determined that Miles Gilburne will qualify as an “audit committee financial expert” as defined in applicable SEC rules. The audit committee is responsible for: • meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; ​ • monitoring the independence of the independent registered public accounting firm; ​ • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; ​ • inquiring and discussing with management our compliance with applicable laws and regulations; ​ 118 TABLE OF CONTENTS • pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; ​ • appointing or replacing the independent registered public accounting firm; ​ • determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; ​ • establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; ​ • monitoring compliance on a quarterly basis with the terms of this offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of this offering; and ​ • reviewing and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our Board of Directors, with the interested director or directors abstaining from such review and approval. ​ Nominating Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a nominating committee of our Board of Directors. The members of our nominating committee will be Miles Gilburne, Dr. Phillip Rösler and Winston Ma and Dr. Phillip Rösler will serve as chairman of the nominating committee. Under the Nasdaq listing standards, we are required to have a nominating committee composed entirely of independent directors. Our Board of Directors has determined that each of Miles Gilburne, Dr. Phillip Rösler and Winston Ma are independent. The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our Board of Directors. The nominating committee considers persons identified by its members, management, shareholders, investment bankers and others.